drugset / Trial / NCT06797024
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
NaSingle-groupOpen-labelTreatment
Summary
his study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory neurologic immune disorders. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed/refractory neurologic immune disorders.
Timeline
- Start
- 2025-02-28
- Primary completion
- 2026-12-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JY231 | Cell therapy | 2e+08 unknown | Intravenous |
| Subject | JY231 | Cell therapy | 4e+08 unknown | Intravenous |
| Subject | JY231 | Cell therapy | 8e+08 unknown | Intravenous |
| Subject | JY231 | Cell therapy | 2e+09 unknown | Intravenous |
| Subject | JY231 | Cell therapy | 4e+09 unknown | Intravenous |
| Subject | JY231 | Cell therapy | 8e+09 unknown | Intravenous |